Zacks Research Issues Optimistic Outlook for STERIS Earnings

STERIS plc (NYSE:STE) – Research analysts at Zacks Research upped their Q2 2027 EPS estimates for shares of STERIS in a report released on Wednesday, November 27th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.58 for the quarter, up from their previous estimate of $2.51. The consensus estimate for STERIS’s current full-year earnings is $9.15 per share.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.02. The company had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.03 EPS.

STE has been the topic of several other research reports. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. JMP Securities reissued a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Monday, November 18th. Stephens reissued an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research note on Thursday, November 7th. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. Finally, KeyCorp raised their target price on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $253.00.

STERIS Stock Up 0.7 %

STERIS stock opened at $219.06 on Monday. The company’s 50 day simple moving average is $225.01 and its 200 day simple moving average is $228.23. STERIS has a fifty-two week low of $195.47 and a fifty-two week high of $248.24. The firm has a market capitalization of $21.62 billion, a price-to-earnings ratio of 50.01 and a beta of 0.85. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 annualized dividend and a yield of 1.04%. STERIS’s dividend payout ratio (DPR) is currently 52.05%.

Insiders Place Their Bets

In other news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 35.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the sale, the senior vice president now owns 11,372 shares in the company, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Institutional Trading of STERIS

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. West Coast Financial LLC raised its holdings in shares of STERIS by 2.8% in the third quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock valued at $398,000 after purchasing an additional 45 shares during the last quarter. Taylor Frigon Capital Management LLC increased its holdings in STERIS by 0.8% during the second quarter. Taylor Frigon Capital Management LLC now owns 6,175 shares of the medical equipment provider’s stock worth $1,356,000 after buying an additional 46 shares during the last quarter. SkyView Investment Advisors LLC increased its holdings in STERIS by 1.6% during the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock worth $765,000 after buying an additional 51 shares during the last quarter. Mather Group LLC. increased its holdings in STERIS by 7.6% during the second quarter. Mather Group LLC. now owns 763 shares of the medical equipment provider’s stock worth $172,000 after buying an additional 54 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in STERIS by 16.5% during the first quarter. EverSource Wealth Advisors LLC now owns 402 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 57 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.